ClinicalTrials.gg
Enrolling by invitationNCT05303428Updated Nov 9, 2026

Study of Low-intensity Focused Ultrasound Effects on Cognitive fMRI Signals

An interventional study of Neuromodulation with low-intensity focused ultrasound in Cognitive Change, sponsored by Virginia Polytechnic Institute and State University. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Virginia Polytechnic Institute and State University · Not applicable, Interventional, and Basic science

How we know

Updated Nov 9, 2026Now Enrolling by invitationFirst site in United States+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Study aims to examine the effects of noninvasive brain stimulation on brain signals. This insight may have potential clinical implications for addiction, pain, and mental health populations. Participants will receive MRI and CT imaging. Participants receive low-intensity focused ultrasound (LIFU) to temporarily change brain activity. Participants then receive fMRI scans to measure changes in both resting and cognitive brain signaling using structured tasks. Heart rate, blood pressure, respiratory rate, and skin moisture is monitored. Participants complete a battery of questionnaires, both behavioral and symptom monitoring. The study takes place over 4 study visits.

02

Conditions studied

  • Cognitive Change
03

In context

Lead sponsor

Virginia Polytechnic Institute and State University is the lead sponsor of 127 studies on the registry; 28 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy volunteers, all ethnicities, who understand and speak English.

Exclusion criteria

Exclusion Criteria:

  1. Claustrophobia (scanning environment may be uncomfortable).
  2. to MRI: including pacemaker, aneurysm clips, neurostimulators, cochlear implants, metal in eyes, steel worker, or other implants.
  3. Contraindications to CT: pregnancy
  4. Active medical disorder or treatment with potential CNS effects (e.g. Alzheimer's)
  5. History of neurologic disorder. (e.g. Parkinson's, Epilepsy, or Essential Tremor)
  6. History of head injury resulting in loss of consciousness for >10 minutes.
  7. History of alcohol or drug dependence (through self-report).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    LIFU, fMRI Cognitive

    fMRI resting and cognitive tasks performed after LIFU application to known brain region of interest or active sham region (within participant all conditions tested).

    Other: Neuromodulation with low-intensity focused ultrasound

Interventions

  • OtherNeuromodulation with low-intensity focused ultrasound

    application of LIFU to induce temporary neuromodulation, effects tested with resting state and task based fMRI scanning.

06

What researchers measure

Primary outcomes

  1. fMRI Signals - Cognition

    Changes in fMRI signals of region of interest during a cognitive task

    Time frame: Participant study duration, approximately 3 weeks.

Secondary outcomes

  1. Executive function task performance

    Testing effects of LIFU on altered task performance

    Time frame: Participant study duration, approximately 3 weeks.

Other outcomes

  1. Assess for changes in physiological measures

    Monitoring for any changes in heartrate, blood pressure, respiratory rate, or galvanic skin response throughout testing

    Time frame: Participant study duration, approximately 3 weeks.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Mar 2026 (actual). Primary completion is estimated for Apr 2028, 25 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Mar 2026, on Nov 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2022
First posted
Mar 31, 2022
StartActual
Mar 10, 2026was Oct 2026
Primary completionEst.
Apr 2028
CompletionEst.
Apr 2028
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Enrolling by invitation
changed Nov 9, 2026
Sites
1 site added — first site in United States
Show site
  • Fralin Biomedical Research Institute at VTC · Roanoke, United States
Nov 9, 2026
Start date
Oct 2026→Mar 10, 2026 (actual)
Nov 9, 2026
Contact
No study contact listed any more: removed l•••@vtc.vt.edu · •••2375
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Not yet recruiting→Enrolling by invitation
    1 site added — first site in United States
    Show site
    • Fralin Biomedical Research Institute at VTC · Roanoke, United States
    Start date Oct 2026→Mar 10, 2026 (now actual)
    Contact No study contact listed any more: removed l•••@vtc.vt.edu · •••2375
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05303428
Responsible party
Wynn Legon (Assistant Professor, Virginia Polytechnic Institute and State University) — Principal investigator
First posted
Mar 31, 2022
Start date
Mar 10, 2026
Primary completion
Apr 2028 (estimated)
Completion
Apr 2028 (estimated)
Last update
Nov 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion